New study aims to unravel muscle loss in advanced stomach cancer
NCT ID NCT06137508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 125 patients with incurable gastroesophageal cancer to measure how much muscle they lose during chemotherapy. Researchers will collect blood, tissue samples, and track treatment side effects and survival. The goal is to better understand why muscle wasting happens and how it affects patients' outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify biological markers and risk factors for muscle wasting, pointing toward future treatments for cachexia.
- What could go wrong
- This is an observational study, not testing a treatment. It may not directly lead to new therapies, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rigshospitalet
Copenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.